Viking Therapeutics, Inc.

NasdaqCM:VKTX 주식 보고서

시가총액: US$5.9b

Viking Therapeutics 대차 대조표 상태

재무 상태 기준 확인 6/6

Viking Therapeutics 의 총 주주 지분은 $911.4M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $937.9M 및 $26.4M 입니다.

주요 정보

0%

부채 비율

US$0

부채

이자 보상 비율n/a
현금US$930.44m
주식US$911.45m
총 부채US$26.44m
총 자산US$937.89m

최근 재무 상태 업데이트

Recent updates

Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations

Nov 04

Viking Therapeutics: Lots Of Positives

Oct 28

Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data

Sep 25

Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth

Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape

Aug 30

Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands

Jul 25

We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth

Viking Therapeutics: Future Weight Loss Heavyweight?

Apr 02

We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Mar 05
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate

Viking Therapeutics: Playing Second Fiddle To Madrigal

Aug 30

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Jul 13
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Revisiting Viking Therapeutics

Apr 20

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Apr 12
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Dec 17
We Think Viking Therapeutics (NASDAQ:VKTX) Can Afford To Drive Business Growth

Viking Therapeutics: Remaining Bullish And Sticking To My Plan

Aug 27

Viking Therapeutics soars 11% on encouraging VK0214 data in rare metabolic disorder

Jun 17

Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Jan 13
Have Insiders Been Selling Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares This Year?

Viking Therapeutics announces senior management appointments

Jan 06

Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Dec 09
Do Institutions Own Viking Therapeutics, Inc. (NASDAQ:VKTX) Shares?

Viking Therapeutics: Progressing Steadily, But Concerns Remain

Nov 29

재무 상태 분석

단기부채: VKTX 의 단기 자산 ( $936.6M )이 단기 부채( $25.7M ).

장기 부채: VKTX 의 단기 자산( $936.6M )이 장기 부채( $755.0K ).


부채 대 자본 내역 및 분석

부채 수준: VKTX 부채가 없습니다.

부채 감소: VKTX 5년 전에 부채가 없었습니다.


대차 대조표


현금 런웨이 분석

과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.

안정적인 현금 활주로: VKTX 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.

예측 현금 활주로: 무료 현금 흐름이 매년 25 %의 역사적 비율로 계속 감소한다면 VKTX ) 3년 이상 충분한 현금 활주로를 보유하고 있습니다.


건강한 기업 발견하기